Dominique Tersago
Chief Tech/Sci/R&D Officer chez CANTARGIA AB
Fortune : - $ au 31/03/2024
Profil
Dominique Tersago is currently the Chief Medical Officer at Cantargia AB since 2022.
Prior to this, she worked as the Chief Medical Officer at Exevir Bio BV from 2020 to 2022 and at Highlight Therapeutics SL from 2017 to 2020.
She also worked as the Chief Medical Officer at Ablynx NV from 2013 to 2015.
Dr. Tersago holds a doctorate degree from the University of Antwerp.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CANTARGIA AB
-.--% | 31/12/2022 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Dominique Tersago
| Sociétés | Poste | Début |
|---|---|---|
| CANTARGIA AB | Chief Tech/Sci/R&D Officer | 01/08/2022 |
Anciens postes connus de Dominique Tersago
| Sociétés | Poste | Fin |
|---|---|---|
Exevir Bio BV
 Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium. | Chief Tech/Sci/R&D Officer | 01/07/2022 |
Highlight Therapeutics SL
 Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain. | Chief Tech/Sci/R&D Officer | 01/03/2020 |
| ABLYNX | Chief Tech/Sci/R&D Officer | 01/11/2015 |
Formation de Dominique Tersago
| University of Antwerp | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CANTARGIA AB | Health Technology |
| Entreprise privées | 3 |
|---|---|
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Highlight Therapeutics SL
Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain. | Health Technology |
Exevir Bio BV
Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium. | Health Technology |
